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Chronic inflammation promotes the development
and progression of various epithelial tumors. Wild-
type p53 suppresses inflammation, but it is unclear
whether the role of p53 in suppression of inflamma-
tion is linked to its tumor suppression function.
Here, we established mouse models of myeloid line-
age-specific p53 deletion or activation to examine
its role in inflammation-related intestinal tumorigen-
esis. Impaired p53 in the myeloid linage resulted in
elevated levels of inflammatorymediators and stimu-
lated adenoma initiation inApcMin/+mice. In contrast,
mice with mild p53 activation in the myeloid lineage
attenuated the inflammatory response and were
more resistant to intestinal tumor development and
invasion, whichwere initiated throughApcMin/+muta-
tion or carcinogen and promoted by colitis. Further-
more, p53 activation also suppressed alternative
(M2) macrophage polarization together with c-MYC
downregulation. Therefore, as a regulator of macro-
phage function, p53 is critical to protection against
tumorigenesis in a non-cell-autonomous manner.
INTRODUCTION
Both clinical and experimental studies have established that
chronic inflammation promotes development and/or progression
of various epithelial tumors (Mantovani et al., 2008). Colitis-asso-
ciated cancer (CAC) is a classic inflammation-driven cancer, and
mouse models of CAC have proved valuable for understanding
general mechanisms connecting inflammation and cancer.
Immune cells infiltrating tumor stroma, such as tumor-associated
macrophages (TAMs), engage in an extensive and dynamic
crosstalk with tumor cells (Balkwill and Mantovani, 2001). Cyto-
kines and chemokines, including interleukin-6 (IL-6) and tumor
necrosis factor alpha (TNF-a), which are produced by activated
immune cells (especially TAMs) in the tumor microenvironment,
control the viability and growth of surrounding epithelial cells
and their malignant derivatives through the necrosis factor kB
(NF-kB) and STAT3 pathways (Bollrath and Greten, 2009).888 Cell Reports 13, 888–897, November 3, 2015 ª2015 The AuthorsAs a major tumor suppressor that responds to stress signals
such as DNA damage and oncogene activation, p53 activation
promotes cell-cycle arrest, apoptosis, or senescence (Vousden
and Prives, 2009). Dysfunctional p53 signaling or p53 mutations
are present in over 80% of all human cancers, including
colorectal cancer (Lozano, 2007). Both MDM2 and MDM4 are
negative regulators of p53, exhibiting non-overlapping and syn-
ergistic roles in inhibiting p53 (Terzian et al., 2007). Under cellular
stress, p53 activation is achieved through disruption of the p53-
MDM2/MDM4 interaction. As a small-molecule antagonist of the
p53-MDM2 protein interaction, Nutlin-3 has been shown to have
activity against human xenografts in preclinical models (Vassilev
et al., 2004). Moreover, restoration of p53 function in p53-defi-
cient tumors or increasing p53 activity in p53 wild-type tumors
has been used to help develop p53-based anticancer treatments
(Lane et al., 2010).
Although the cell-autonomous function of p53 on tumor sup-
pression has been extensively studied, a few studies also sug-
gest that stromal p53 has an inhibitory effect on cancer growth
(Kiaris et al., 2005; Schauer et al., 2013), angiogenesis (Nishizaki
et al., 1999), and invasion and metastasis (Kang et al., 2009;
Moskovits et al., 2006). In a mouse model of prostate cancer,
epithelial tumorigenesis imposes a strong selective pressure
for loss of p53 in tumor-associated fibroblasts (Hill et al.,
2005). Furthermore, ablation of p53-dependent senescence
in hepatic stellate cells increases cirrhosis and reinforces the
transformation of adjacent epithelial cells into hepatocellular car-
cinoma (Lujambio et al., 2013). Therefore, it seems that p53
could render tumor microenvironment less conducive for tumor
development.
A number of reports point to the potential involvement of p53 in
inflammation control in processes including collagen-induced
arthritis (Yamanishi et al., 2002) and bleomycin-induced lung
fibrosis (Ghosh et al., 2002). Higher levels of induction of various
pro-inflammatory factors were found in macrophages from p53-
null mice (Zheng et al., 2005). Mechanisms of p53 in control of
immunity may involve its direct repression of promoter activity
of NF-kB subunit p65, as well as negative regulation of the tran-
scriptions of NF-kB-dependent genes, including Il-6, Cox-2,
Nos2, and others (Cooks et al., 2014).
It remains to be determined whether the role of p53 in inflam-
mation is involved in modulating the tumor microenvironment
and tumor suppression. In this study, we established genetic
mouse models with p53 deletion or activation specifically in the
myeloid lineage during intestinal tumorigenesis. Our results
reveal a functional role for p53 in tumor suppression in a non-
cell-autonomous manner through modulation of the tumor in-
flammatory microenvironment.
RESULTS
p53 Deficiency in Myeloid Lineage Accelerated
Tumorigenesis in ApcMin/+ Mice
In order to study the potential role of p53 in myeloid lineage
on mouse intestinal tumorigenesis, we first deleted p53 in
myeloid lineage by crossing LysM-Cre (Clausen et al., 1999)
and p53Flox/Flox (Jonkers et al., 2001) mice. Recombination of
p53 allele was present in peritoneal exudate cells (PECs) from
LysM-Cre; p53Flox/+ (LysM-p53Flox/+) mice (Figure S1A). With
deletion efficiency at around 80% (Figure S1B), LysM-p53Flox/Flox
mice developed normally and did not exhibit overt phenotypes
up to 4 months of age (Figure S1C). However, higher expression
of inflammatory cytokines and Nos2 both in naive PECs (Fig-
ure 1A) and PECs under stimulation of lipopolysaccharide
(LPS) (Figure 1B) were found in LysM-p53Flox/Flox mice, as
compared with the p53Flox/Flox control littermates. Next, we
crossed LysM-p53Flox/Flox mice with the adenoma prone
ApcMin/+ mice (Moser et al., 1990). Strikingly, at 100 days of
age, loss of one allele of p53 in myeloid lineage was able to
increase the total number of intestinal adenomas by nearly
2-fold (Figures 1C and 1D). Higher tumor burdens in ApcMin/+;
LysM-p53Flox/+ mice were found throughout the small intestine
covering proximal to distal regions (Figure 1E). A small cohort
of ApcMin/+; LysM-p53Flox/Flox mice examined also exhibited an
increased adenoma incidence in the small intestine, similar to
ApcMin/+; LysM-p53Flox/+ mice (Figure 1D).
Although tumor size distribution, tumor cell proliferating rate,
and macrophage infiltration were comparable between 100-
day-old ApcMin/+; p53Flox/+ and ApcMin/+; LysM-p53Flox/+ mice
(Figures S1D–S1F), quantification of microadenomas in 4- to
5-week-old mice indicated much higher adenoma initiation in
ApcMin/+; LysM-p53Flox/+ mice (Figure 1F), possibly accounting
for their increased tumorigenesis observed at 3–4 months of
age. In addition, markedly increased expression ofmRNAs for in-
flammatory cytokines and chemokine was found in tumors from
ApcMin/+; LysM-p53Flox/+ mice (Figure 1G).
Collectively, impaired p53 in myeloid lineage promoted
elevated level of inflammatory cytokines and led to enhanced ad-
enoma initiation and higher tumor burdens in ApcMin/+ mice.
Mild p53 Activation in Myeloid Lineage Attenuated
Tumor Progression in ApcMin/+ Mice
Under chronic inflammatory conditions such as ulcerative colitis
(UC), p53 could be activated through phosphorylation at serine
15 (Hofseth et al., 2003). We also found myeloid cells with acti-
vated p53 in the stroma of UC tissues from mice treated with
3%of dextran sulfate sodium (DSS) (Figure S2A). Tissue-specific
Mdm2 and Mdm4 double heterozygous mice can be used to
model moderate p53 activation elicited by stress signals (Zhang
et al., 2012). We therefore generated mice heterozygous for
Mdm2 in the Mdm4+/ background (Grier et al., 2006; XiongCeet al., 2006) specifically in myeloid lineage. The recombined
Mdm2 allele could be detected in bone marrow of LysM-Cre;
Mdm2FM/+; Mdm4+/ (LysM-MM) mice (Figure S2B). In addition,
genetic recombination as indicated by X-gal staining in aRosa 26
reporter background from these mice were found limited in the
intestinal epithelial lumen where myeloid cells resided (Fig-
ure S2C) and in the PEC cells (Figure S2D). The LysM-MM
mice were viable, with similar hemogram parameters and histo-
logical features compared with the control mice (Figures S2E
and S2F). The number of total and mature macrophages was
comparable with the LysM-p53Flox/+ or control mice (Figures
S2G, S2H, and S2J). Fluorescence-activated cell sorting
(FACS) analyses confirmed similar cell-cycle and survival status
of these macrophages (Figure S2I). As expected, a moderate
elevation of both p53 protein levels (Figure S2K) and the expres-
sion of its common downstream targets (Figure S2L) was found
in PECs from the LysM-MM mice. Under LPS stimulation, the
LysM-MM PECs exhibited reduced levels of IL-6, IL-1b, and
IL-12p40 as well as mRNA level of Nos2 (Figures S2M and
S2N), suggesting anti-inflammatory roles for p53 activation in
myeloid cells.
The LysM-MM mice did not exhibit any tumorigenic pheno-
types in GI tract up to 13months of age (Figure S3A). When these
mice were crossed to the ApcMin/+ background, dramatic reduc-
tions (about 50%) in the number of intestinal adenomas were
found in both the small intestine and colon of 2- to 4-month-
old ApcMin/+; LysM-MM mice, compared with the ApcMin/+;
Mdm2FM/+; Mdm4+/ (ApcMin/+ control) mice (Figures 2A–2C).
On average, ApcMin/+ control mice died within 200 days of age
from complications of intestinal tumors (Moser et al., 1990). In
contrast, the overall survival of ApcMin/+; LysM-MM mice was
prolonged to 293 days (Figure 2D). b-Gal immunostaining indi-
cated specific Cre-mediated recombination in the infiltrated
myeloid cells of tumors from ApcMin/+; Rosa26; LysM-MM mice
(Figure S3B). Although adenoma initiation seemed to be similar
in both genotypes of mice at 4–5 weeks of age (Figures 2E and
2F), an increase in small size tumors (<1 mm in diameter) and a
decrease in larger size tumors (2–3 mm in diameter) were found
in ApcMin/+; LysM-MMmice at the age of 3–4months (Figures 2G
and S3C), suggesting that p53 activation affected tumor pro-
gression in this setting. The incidence and size of a tumor can
be influenced by a balance of cell proliferation and death within
the tumor mass. Higher apoptotic index (an 82% increase) and
lower proliferative index (a 56% decrease) were found in the
size-matched tumors from ApcMin/+; LysM-MMmice, compared
with ApcMin/+ control mice (Figures 2H and 2I). In addition, there
were markedly reduced expressions of Cox-2 as well as pro-
inflammatory cytokines and chemokine in ApcMin/+; LysM-MM
tumors (Figure 2J). Immunofluorescence staining confirmed
the attenuated COX-2 expression in the infiltrating macrophages
from ApcMin/+; LysM-MM tumors (Figure 2K). Similar frequency
of myeloid cells infiltration in tumors (Figure 2K) also suggested
that the differences in cytokine expression might not result
from the difference of macrophage recruitment.
Therefore, p53-dependent signaling in myeloid cells was
critically involved in the downregulation of critical pro-inflamma-
tory cytokines and modifier genes, together with an inhibition of
tumor growth in ApcMin/+ mice.ll Reports 13, 888–897, November 3, 2015 ª2015 The Authors 889
Figure 1. p53 Deficiency in Myeloid Lineage Accelerated Tumorigenesis in ApcMin/+ Mice
(A) Relative gene expression normalized to Hprt in naive PECs from p53Flox/Flox and LysM-p53Flox/Flox mice.
(B) Expressions of Nos2, Il-1b, and Il12 in LPS-stimulated PECs from p53Flox/Flox and LysM-p53Flox/Flox mice at different time points were normalized to Hprt.
Values are means ± SEMs, p < 0.001 (two-way ANOVA).
(C) Representative small intestinal segments with visible polyps from ApcMin/+; p53Flox/+ and ApcMin/+; LysM-p53Flox/+mice at 100 days of age.
(D) Quantifications of polyps on longitudinal sections throughout small intestines. Values are means ± SEMs, *p < 0.05; ***p < 0.001 (one-way ANOVA
with Dunnett’s multiple comparisons).
(E) Numbers of the polyps in ApcMin/+; p53Flox/+ and ApcMin/+; LysM-p53Flox/+ mice stratified by small intestinal region. Values are means ± SEMs, p < 0.001
(two-way ANOVA).
(F) Microadenomas were quantified over H&E-stained sections from 4- to 5-week-old mice throughout the intestine.
(G) Relative mRNA expressions in size-matched polyps of 100-day-old mice. Values are means ± SEMs, **p < 0.01; ***p < 0.001 (t test).
See also Figure S1.
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Figure 3. LysM-MM Mice Were More
Resistant to Colitis-Associated Colorectal
Tumorigenesis
(A) Daily body weight of control and LysM-MM
mice during AOM/DSS treatment.
(B) Macroscopic view of distal colons and total
colorectal tumor incidence at the end of AOM/DSS
treatment (day 80). Scale bar, 5 mm. Values are
means ± SEMs, p = 0.006 (t test).
(C) Grading of tumors in each genotype. Note a
lack of invasive adenocarcinomas in LysM-MM
mice.
(D) Representative images of graded colorectal
tumors of control and LysM-MM mice. Arrows
indicated invasive adenocarcinomas. Scale bar,
200 mm.
(E) Immunostaining of phspho-STAT3 on the AOM/
DSS-induced tumors in control and LysM-MM
mice. Scale bar, 50 mm.
(F) Macroscopic view and tumor incidence in co-
lons of DSS-treated ApcMin/+ control and ApcMin/+;
LysM-MM mice. Scale bar, 5 mm. Values are
means ± SEMs, p = 0.0247 (t test).
(G) Images of colon adenocarcinomas (left) and
their submucosa (right, boxed area in left). Scale
bar, 100 mm.
See also Figure S4.LysM-Cre; Mdm2FM/+; Mdm4+/ Mice Were More
Resistant to Colitis-Associated Colorectal Tumor
Invasion
Inflammatory stimulus was a strong promoter following the
initiating genetic alterations in colon carcinogenesis. We
induced the CAC model by injecting a single dose of the pro-
carcinogen azoxymethane (AOM), followed by repeated ad-
ministrations of the irritant DSS on 6- to 8-week-old control
and LysM-MM mice (Figure S4A) as previously reported
(Greten et al., 2004). Repeated DSS administration promotes
tissue damage and chronic inflammation, which greatly
increases the incidence of AOM-induced tumors, thereby
mimicking inflammatory bowel disease (IBD). Changes in
body weight were monitored daily and colorectal tumor bur-
dens were determined 80 days after the initial AOM treatment.
Throughout the treatment, LysM-MM mice exhibited less bodyFigure 2. Attenuated Tumor Progression in ApcMin/+; LysM-MM Mice
(A) Representative small intestinal segments of ApcMin/+ control and ApcMin/+; Ly
(B and C) Quantifications of polyps on longitudinal sections throughout small inte
(D) Long-term survival of the ApcMin/+ control (n = 52) and ApcMin/+; LysM-MM (n
(E and F) Representative morphology (E) and quantification (F) of microadenoma
(G) Size distribution of tumors from 3- to 4-month-old mice. Values are means ±
(H) TUNEL (left, red) and BrdU labeling (right) of tumors from 2- to 3-month-old A
(I) Apoptotic and proliferative indices in tumors measured by TUNEL and BrdU sta
(J) Relative mRNA expressions of inflammatory-related genes normalized to Hp
(nR 5) at 100 days of age. Values are means ± SEMs. *p < 0.05; **p < 0.01; ***p
(K) Representative immunofluorescence staining for CD11b (green) andCOX-2 (re
old ApcMin/+ control and ApcMin/+; LysM-MM mice. Scale bar, 100 mm.
See also Figures S2 and S3.
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LysM-MM mice showed a lower frequency of colorectal
tumors (a 40% decrease), accompanied with less enlarged
spleens and mesenteric lymph nodes, as opposed to control
mice (Figures 3B and S4C).
Histological examination and grading of tumors were per-
formedover the full length of theH&E-stained colons (FigureS4B)
according to the standards reported previously (Cooper et al.,
2001). Among 71 tumors analyzed from control mice, 21 of
them (29.6%) were determined as high-grade dysplasia, and
14 tumors (19.7%) were classified as invasive adenocarcinomas
(Figures 3C and 3D, red arrows). In contrast, among 45 tumors in
the colon of LysM-MM mice, although 17 (37.8%) were deter-
mined as high-grade dysplasia, none were found to be invasive
(Figures 3C and 3D). Furthermore, pTyr-STAT3 staining, as an
indicator of inflammation, was virtually absent from LysM-MMsM-MM mice at 3 months of age. Arrows indicated visible polyps.
stine (B) and colon (C). Values are means ± SEMs. *p < 0.05; **p < 0.01 (t test).
= 30) mice (p = 0.0003, Mantel-Cox/log-rank test).
s from 4- to 5-week-old mice. Scale bar, 100 mm.
SEMs. **p < 0.01; ***p < 0.001 (two-way ANOVA).
pcMin/+ control and ApcMin/+; LysM-MM mice. Scale bar, 100 mm.
ining shown in (H), respectively. Values are means ± SEMs. ***p < 0.001 (t test).
rt in size-matched polyps of ApcMin/+; control and ApcMin/+; LysM-MM mice
< 0.001 (t test).
d) in size-matched polyps (T) and normal intestinal epithelium (N) from 3-month-
Figure 4. p53 Status Influenced Alternative Activation of Macrophages
(A and B) Expression of M2-related genes in polyps was assessed by qRT-PCR. Size-matched polyps were from at least six mice in each group.
(C) Representative immunofluorescence staining for CD206 (green) and F4/80 (red) in size-matched polyps (T) and normal intestinal epithelium (N) from 3-month-
old ApcMin/+ control and ApcMin/+; LysM-MM mice. Scale bar, 100 mm.
(legend continued on next page)
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tumors, in sharp contrast to the tumors of the control mice
(Figure 3E).
Although ApcMin/+ mice develop benign tumors mainly in the
small intestine, strong inflammatory stimuli such as DSS treat-
ment promote the development and growth of colorectal neo-
plasms (Tanaka et al., 2006). Reminiscent of our findings in the
AOM/DSS model, after 5 weeks of low-dose DSS treatment, a
lower frequency of colorectal tumors appeared in DSS-treated
ApcMin/+; LysM-MM mice as compared to ApcMin/+ control
mice (Figures S4D and 3F). Although invasive adenocarcinomas
were found in four of six ApcMin/+ control mice examined, none of
the tumors were found to be invasive in five ApcMin/+; LysM-MM
mice (Figure 3G). Tumor invasion was also not observed in the
ApcMin/+; LysM-MM mice under another treatment scheme of
DSS (Cooper et al., 2001) (Figures S4E–S4G).
Collectively, these observations indicated that increased p53
signaling in myeloid lineage suppressed inflammation-promoted
tumor progression and invasion.
Alternative Macrophages Polarization in Tumors Was
Influenced by p53 Status
Besides the tumor promoting roles of the pro-inflammatory cyto-
kines, it is also well known that some TAMs exhibited features of
an alternatively activated (M2) phenotype, which is associated
with tumor angiogenesis, progression, invasion, and evading im-
mune surveillance (Erreni et al., 2011). We therefore examined
whether p53 status in myeloid lineage might also modulate the
M2 phenotypes of TAMs in the intestinal tumors. Indeed, when
compared with the size-matched ApcMin/+; p53Flox/+ tumors,
genes associated with M2 phenotype including Arg-1, Ym-1,
MR, and Trem2 were significantly upregulated in tumors from
ApcMin/+; LysM-p53Flox/+ mice (Figure 4A). Conversely, the ex-
pressions of M2-related genes were reduced in ApcMin/+; LysM-
MM tumors (Figure 4B). The distribution of macrophages with
M2 marker in ApcMin/+ polyps was further detected by immuno-
staining. F4/80 and CD206 double-positive macrophages were
scarcely detected in the stroma of ApcMin/+; LysM-MM polyps
but infiltrated significantly into the stroma of ApcMin/+ control
polyps (Figure 4C).Moreover, onlyminor staining of CD206 could
be detected in the normal intestinal epithelium (Figure 4C).
To examine whether p53 activation in macrophages would
directly retard an M2 phenotype in vitro, we stimulated PECs un-
der M2-polarizing conditions. Induction of M2-associated genes
was substantially downregulated in LysM-MM PECs after 24 hr
of IL-4 treatment (Figure 4D). With the treatment of p53 small-
molecule activator Nutlin-3, IL-4-induced mRNA expression of
M2 markers was significantly suppressed (Figure 4E). c-MYC
was recently recognized as a key regulator in alternative macro-
phage activation. c-MYC blockade in macrophages showed an
inhibitory effect on the IL-4-dependent induction of about 45%
of all M2 genes (Pello et al., 2012). Although strong induction(D) mRNA expressions in PECs from control and LysM-MM mice under the treat
(E) mRNA expressions of PECs from C57/BL6 mice under the treatment of Nutlin
(F) c-Myc expression in peritoneal macrophages after exposure to IL-4 for 24 hr.
(G) Western blot analysis on RAW 264.7 cells under the treatment of IL-4 (20 ng/
(H) Quantifications of protein expression levels in (F) normalized against GAPDH
Values are means ± SEMs, *p < 0.05; **p < 0.01; ***p < 0.001 (t test).
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rophages, significant downregulation of c-Myc were found both
in PECs from LysM-MM mice and in PECs administrated with
IL-4 and Nutlin-3 (Figure 4F). Western blot analysis on RAW
264.7 cells confirmed a lower expression level of c-MYC protein
accompanied with p53 activation (Figures 4G and 4H).
DISCUSSION
Tumor microenvironment contributes significantly to the devel-
opment of tumors by affecting tumor initiation, progression, or
metastasis, depending on specific contexts. The most obvious
tumor promoting role is from macrophages, which have been
manifested in inflammation-associated cancers. In this study,
we report a functional role of p53 in tumor suppression in a
non-cell-autonomous manner through modulating myeloid line-
age cells associated with the tumor inflammatory microenviron-
ment. Activation of p53 also downregulates c-MYC and sup-
presses alternative macrophage activation. Our genetic studies
clearly demonstrate that p53 exerts important functions in the
myeloid lineage, which is critical for protection against intestinal
tumorigenesis.
Growing evidence supports that the pro-inflammatory cyto-
kines are essential mediators of the origin cause ofmany cancers
through the interactions between pre-neoplastic epithelium and
surrounding activated immune cells (Bollrath and Greten, 2009).
Breakdown of the protective intestinal barriers and chronic intes-
tinal inflammation is intimately associated with tumorigenesis in
the GI tract (Grivennikov et al., 2012). Persistent chronic inflam-
mation could induce DNA damage and oncogenic mutations
through intermediates such as reactive oxygen and nitrogen
species (ROS and RNI) (Hussain et al., 2003). Another mecha-
nism through which inflammation may trigger adenoma initiation
is from elevated NF-kB signaling, which enhancesWnt activation
and induces transformation and expansion of crypt stem cells
that acquire tumor-initiating capacity (Schwitalla et al., 2013a).
Of note, p53 mutations are enriched in inflamed colonic tissue
well before neoplastic lesions become detectable (Hussain
et al., 2000). Altogether, these inflammation-associated pro-
cesses contribute to enhanced mutagenesis required for ade-
noma initiation. Previous studies have shown that high amounts
of Nos2 (or iNOS) led to earlier tumor onset in mice with intestinal
epithelial-cell-specific deletion of Apc (Shaked et al., 2012).
Conversely, inhibition of Nos2 can attenuate formation of ade-
nomas in ApcMin/+ mice (Ahn and Ohshima, 2001). Interestingly,
p53 is known to inhibit Nos2 expression (Forrester et al., 1996).
Here, we found much higher frequencies of microadenoma initi-
ation at a very early stage in ApcMin/+; LysM-p53Flox/+ mice. High
expression of Nos2 and the pro-inflammatory cytokines in
naive PECs from LysM-p53Flox/Flox mice as well as in tumors
from ApcMin/+; LysM-p53Flox/+ mice possibly contributed to thement of IL-4 (20 ng/ml) for 24 hr.
-3 (10 mM) and/or IL-4 (20 ng/ml) for 24 hr.
ml) with or without Nutlin-3 (10 mM).
.
increased adenoma initiation. In addition, the antioxidant func-
tion of p53 (Sablina et al., 2005)may also help tomaintain a redox
balance in the microenvironment during early microadenoma
initiation.
Aside from tumor initiation, chronic inflammation present dur-
ing CAC development can influence all proposed stages of tu-
mor progression and metastatic dissemination (Terzic et al.,
2010). A great deal of evidence implicates p53 as playing an
instrumental role in suppressing CAC. p53 mutations occur as
an early genetic change in IBD-associated cancers (Brentnall
et al., 1994). When exposed to DSS, mice harboring a germline
p53 mutation develop severe chronic inflammation and persis-
tent tissue damage and are highly prone to inflammation-asso-
ciated colon cancer, with augmented NF-kB activation found in
tumors (Cooks et al., 2013). Loss of p53 in intestinal epithelium
also resulted in the formation of an NF-kB-dependent inflamma-
tory microenvironment, induction of epithelial-mesenchymal
transition (EMT) and further lymph node metastasis in a colo-
rectal cancer mouse model (Schwitalla et al., 2013b). EMT
can be influenced by NF-kB and/or STAT3 signaling and be
regulated by various pro-inflammatory cytokines (Terzic et al.,
2010). Therefore, NF-kB and STAT3 are instrumental in immune
cells for the production of pro-inflammatory cytokines, which
enforce a feedforward loop to activate STAT3 and NF-kB in
invading cancer cells to stimulate their proliferation, survival,
and metastatic spread (Bollrath and Greten, 2009). In our
mouse models, activation of p53 in tumor microenvironment
attenuated tumor proliferation and invasion in a non-cell-auton-
omous manner. While AOM/DSS-treated mice and DSS-treated
ApcMin/+ mice exhibited obvious tumor invasions, no tumor
invasion was found in mice with activated p53 in myeloid line-
age under the same treatments, which was accompanied with
dampened activation of STAT3 pathways. Collectively, while
the mutual interactions between tumor cells and their microen-
vironment seem to form ‘‘vicious cycles’’ to promote tumorigen-
esis, p53 may critically act in both cell compartments to atten-
uate the inflammatory response and alleviate such exacerbating
effects.
Under certain circumstances, macrophages would be ‘‘re-
educated’’ to alternative activated (M2) TAMs by tumor cells af-
ter infiltrating into the tumors (Hagemann et al., 2008) and further
promote tumor progression in a number of experimental models.
Here, consistent with a most recent report demonstrating the
role of p53 in inhibiting the M2 phenotype (Li et al., 2015), we
further demonstrated that the alternative polarization of macro-
phages in ApcMin/+ tumors was also influenced by p53 status
and might be another mechanism for p53 to modulate the tumor
microenvironment. Therefore, the abilities of p53 to repress the
expressions of cytokines and inflammatory-related molecules
that may belong to either M1 or M2 categories suggested that
p53 may play an important role in attenuating the inflammatory
response and polarization of macrophages during tumorigen-
esis. Given the highly plastic, dynamic, or even mixed pheno-
types of macrophages during tumorigenesis (Biswas and Man-
tovani, 2010; Martinez and Gordon, 2014), these results
underscored the various inducers and the resulting complex
phenotypes of the macrophages existed in the tumors and the
impacts of p53 on these diverse set of macrophages. Recently,Ceclinical relevant tumor therapies are under development aiming
to target both the pro-inflammatory-related molecules including
TNF-a, IL-6, and IL-4-related M2 factors (Ruffell and Coussens,
2015). In this regard, p53 activation in macrophages may help to
control the expressions of both types of genes and serve as a
therapeutic option.
Taken together, our results suggest that p53 activation within
cells of tumor microenvironment is able to inhibit tumor growth
and malignant progression. Activation of stromal p53 by chemo-
therapy or radiotherapy might be part of the mechanisms by
which these treatments cause cancer regression (Bar et al.,
2010). Although additional studies are needed for more mecha-
nistic insights on how p53 might influence the state and
response in the tumor inflammatory microenvironment in more
details, our findings here highlight a non-cell-autonomous tu-
mor-suppressive function of p53. Importantly, our study sug-
gested a possible development of therapeutic strategies in
inflammation-associated cancer patients through pharmacolog-
ical activation of p53 in tumor microenvironment.
EXPERIMENTAL PROCEDURES
Mice
Mice were bred and maintained under specific pathogen-free conditions, and
experiments were conducted in accordance with the institutional animal care
and use committee at Model Animal Research Center of Nanjing University.
C57BL/6J-LysM-cremice (Clausen et al., 1999) obtained from Jackson Labo-
ratory were crossed to Mdm4+/; Mdm2FM/FM mice (Grier et al., 2006; Xiong
et al., 2006) and p53Flox/Flox mice (Jonkers et al., 2001) from MMHCC.
C57BL/6J-ApcMin/+ mice (Moser et al., 1990) from Jackson Laboratory were
crossed to LysM-cre; MM mice or LysM-cre; p53Flox/Flox mice. p53Flox/Flox
mice were backcrossed to C57BL/6 background for at least five generations.
Mdm4+/; Mdm2FM/FM mice were backcrossed to C57BL/6 background for
four generations. To examine AOM/DSS-induced tumorigenesis, mice had
been backcrossed to a FVB/NJ background for five generations. In all exper-
iments, littermate controls were used.
Immunohistochemistry and Immunofluorescent Analyses
Paraffin-embedded slides were de-paraffinized and rehydrated. Antigen un-
masking was performed by steaming slides in 10 mM sodium citrate buffer
(pH 6.0) for 20 min. For phospho-Stat3 monoclonal antibody (Cell Signaling
Technology), antigen retrieval was performed in Tris-EDTA buffer (pH
9.0). Frozen tissue sections were incubated with the following antibodies:
anti-b-catenin (Cell Signaling Technology), anti-COX-2 (Maixin), anti-CD11b
(eBioscience), anti-F4/80 (eBioscience), anti-Ki-67 (Dako), and anti-phos-
pho-Ser-15-p53 (Cell Signaling Technology) overnight at 4C. After washing
the sections, secondary antibodies (Jackson ImmunoResearch) were used.
Nuclei were counterstained with Hoechst 33258 (Sigma-Aldrich). Fluores-
cence was evaluated using a Leica TCS SP2 confocal laser scanning micro-
scope, or Olympus FV 1000 confocal microscope.
Statistical Analysis
Data are expressed asmean ±SEM of at least three independent experiments.
Statistical analyses were carried out using GraphPad Prism 5 and 6 software.
Specific tests used were unpaired t test, log-rank analysis, two-way ANOVA,
and one-way ANOVA with Dunnett’s multiple comparisons. All p values less
than 0.05 were considered statistically significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and four figures and can be found with this article online at http://dx.doi.org/
10.1016/j.celrep.2015.09.045.ll Reports 13, 888–897, November 3, 2015 ª2015 The Authors 895
ACKNOWLEDGMENTS
We thank G. Lozano (MD Anderson Cancer Center) for theMdm2- andMdm4-
deficient mice and J.H. Liu for RAW 264.7 cells. We also wish to thank P. Zhou
for technical support. This work was supported by grants fromNatural Science
Foundation of China (30871265, 31171305) and National High-Tec R&D pro-
gram of China (863 program) (2014AA021606) to G.L.
Received: October 12, 2014
Revised: February 12, 2015
Accepted: September 15, 2015
Published: October 22, 2015
REFERENCES
Ahn, B., and Ohshima, H. (2001). Suppression of intestinal polyposis in
Apc(Min/+) mice by inhibiting nitric oxide production. Cancer Res. 61, 8357–
8360.
Balkwill, F., and Mantovani, A. (2001). Inflammation and cancer: back to
Virchow? Lancet 357, 539–545.
Bar, J., Moskovits, N., and Oren, M. (2010). Involvement of stromal p53 in tu-
mor-stroma interactions. Semin. Cell Dev. Biol. 21, 47–54.
Biswas, S.K., and Mantovani, A. (2010). Macrophage plasticity and interaction
with lymphocyte subsets: cancer as a paradigm. Nat. Immunol. 11, 889–896.
Bollrath, J., and Greten, F.R. (2009). IKK/NF-kappaB and STAT3 pathways:
central signalling hubs in inflammation-mediated tumour promotion and
metastasis. EMBO Rep. 10, 1314–1319.
Brentnall, T.A., Crispin, D.A., Rabinovitch, P.S., Haggitt, R.C., Rubin, C.E., Ste-
vens, A.C., and Burmer, G.C. (1994). Mutations in the p53 gene: an early
marker of neoplastic progression in ulcerative colitis. Gastroenterology 107,
369–378.
Clausen, B.E., Burkhardt, C., Reith, W., Renkawitz, R., and Fo¨rster, I. (1999).
Conditional gene targeting in macrophages and granulocytes using LysMcre
mice. Transgenic Res. 8, 265–277.
Cooks, T., Pateras, I.S., Tarcic, O., Solomon, H., Schetter, A.J., Wilder, S.,
Lozano, G., Pikarsky, E., Forshew, T., Rosenfeld, N., et al. (2013). Mutant
p53 prolongs NF-kBactivation and promotes chronic inflammation and inflam-
mation-associated colorectal cancer. Cancer Cell 23, 634–646.
Cooks, T., Harris, C.C., and Oren, M. (2014). Caught in the cross fire: p53 in
inflammation. Carcinogenesis 35, 1680–1690.
Cooper, H.S., Everley, L., Chang, W.-C., Pfeiffer, G., Lee, B., Murthy, S., and
Clapper, M.L. (2001). The role of mutant Apc in the development of dysplasia
and cancer in the mouse model of dextran sulfate sodium-induced colitis.
Gastroenterology 121, 1407–1416.
Erreni, M., Mantovani, A., and Allavena, P. (2011). Tumor-associated Macro-
phages (TAM) and Inflammation in Colorectal Cancer. Cancer Microenviron.
4, 141–154.
Forrester, K., Ambs, S., Lupold, S.E., Kapust, R.B., Spillare, E.A., Weinberg,
W.C., Felley-Bosco, E., Wang, X.W., Geller, D.A., Tzeng, E., et al. (1996). Nitric
oxide-induced p53 accumulation and regulation of inducible nitric oxide syn-
thase expression by wild-type p53. Proc. Natl. Acad. Sci. USA 93, 2442–2447.
Ghosh, S., Mendoza, T., Ortiz, L.A., Hoyle, G.W., Fermin, C.D., Brody, A.R.,
Friedman, M., and Morris, G.F. (2002). Bleomycin sensitivity of mice express-
ing dominant-negative p53 in the lung epithelium. Am. J. Respir. Crit. Care
Med. 166, 890–897.
Greten, F.R., Eckmann, L., Greten, T.F., Park, J.M., Li, Z.W., Egan, L.J., Kagn-
off, M.F., and Karin, M. (2004). IKKbeta links inflammation and tumorigenesis in
a mouse model of colitis-associated cancer. Cell 118, 285–296.
Grier, J.D., Xiong, S., Elizondo-Fraire, A.C., Parant, J.M., and Lozano, G.
(2006). Tissue-specific differences of p53 inhibition by Mdm2 and Mdm4.
Mol. Cell. Biol. 26, 192–198.
Grivennikov, S.I., Wang, K., Mucida, D., Stewart, C.A., Schnabl, B., Jauch, D.,
Taniguchi, K., Yu, G.Y., Osterreicher, C.H., Hung, K.E., et al. (2012). Adenoma-896 Cell Reports 13, 888–897, November 3, 2015 ª2015 The Authorslinked barrier defects and microbial products drive IL-23/IL-17-mediated
tumour growth. Nature 491, 254–258.
Hagemann, T., Lawrence, T., McNeish, I., Charles, K.A., Kulbe, H., Thompson,
R.G., Robinson, S.C., and Balkwill, F.R. (2008). ‘‘Re-educating’’ tumor-associ-
ated macrophages by targeting NF-kappaB. J. Exp. Med. 205, 1261–1268.
Hill, R., Song, Y., Cardiff, R.D., and Van Dyke, T. (2005). Selective evolution of
stromal mesenchyme with p53 loss in response to epithelial tumorigenesis.
Cell 123, 1001–1011.
Hofseth, L.J., Saito, S., Hussain, S.P., Espey, M.G., Miranda, K.M., Araki, Y.,
Jhappan, C., Higashimoto, Y., He, P., Linke, S.P., et al. (2003). Nitric oxide-
induced cellular stress and p53 activation in chronic inflammation. Proc.
Natl. Acad. Sci. USA 100, 143–148.
Hussain, S.P., Amstad, P., Raja, K., Ambs, S., Nagashima, M., Bennett, W.P.,
Shields, P.G., Ham, A.J., Swenberg, J.A., Marrogi, A.J., and Harris, C.C.
(2000). Increased p53 mutation load in noncancerous colon tissue from ulcer-
ative colitis: a cancer-prone chronic inflammatory disease. Cancer Res. 60,
3333–3337.
Hussain, S.P., Hofseth, L.J., and Harris, C.C. (2003). Radical causes of cancer.
Nat. Rev. Cancer 3, 276–285.
Jonkers, J., Meuwissen, R., van der Gulden, H., Peterse, H., van der Valk, M.,
and Berns, A. (2001). Synergistic tumor suppressor activity of BRCA2 and p53
in a conditional mouse model for breast cancer. Nat. Genet. 29, 418–425.
Kang, S.Y., Halvorsen, O.J., Gravdal, K., Bhattacharya, N., Lee, J.M., Liu,
N.W., Johnston, B.T., Johnston, A.B., Haukaas, S.A., Aamodt, K., et al.
(2009). Prosaposin inhibits tumor metastasis via paracrine and endocrine
stimulation of stromal p53 and Tsp-1. Proc. Natl. Acad. Sci. USA 106,
12115–12120.
Kiaris, H., Chatzistamou, I., Trimis, G., Frangou-Plemmenou, M., Pafiti-Kondi,
A., and Kalofoutis, A. (2005). Evidence for nonautonomous effect of p53 tumor
suppressor in carcinogenesis. Cancer Res. 65, 1627–1630.
Lane, D.P., Cheok, C.F., and Lain, S. (2010). p53-based cancer therapy. Cold
Spring Harb. Perspect. Biol. 2, a001222.
Li, L., Ng, D.S., Mah, W.C., Almeida, F.F., Rahmat, S.A., Rao, V.K., Leow, S.C.,
Laudisi, F., Peh, M.T., Goh, A.M., et al. (2015). A unique role for p53 in the
regulation of M2 macrophage polarization. Cell Death Differ. 22, 1081–1093.
Lozano, G. (2007). The oncogenic roles of p53mutants in mousemodels. Curr.
Opin. Genet. Dev. 17, 66–70.
Lujambio, A., Akkari, L., Simon, J., Grace, D., Tschaharganeh, D.F., Bolden,
J.E., Zhao, Z., Thapar, V., Joyce, J.A., Krizhanovsky, V., and Lowe, S.W.
(2013). Non-cell-autonomous tumor suppression by p53. Cell 153, 449–460.
Mantovani, A., Allavena, P., Sica, A., and Balkwill, F. (2008). Cancer-related
inflammation. Nature 454, 436–444.
Martinez, F.O., and Gordon, S. (2014). The M1 and M2 paradigm of macro-
phage activation: time for reassessment. F1000Prime Rep. 6, 13.
Moser, A.R., Pitot, H.C., and Dove, W.F. (1990). A dominant mutation that pre-
disposes to multiple intestinal neoplasia in the mouse. Science 247, 322–324.
Moskovits, N., Kalinkovich, A., Bar, J., Lapidot, T., and Oren, M. (2006). p53
Attenuates cancer cell migration and invasion through repression of SDF-1/
CXCL12 expression in stromal fibroblasts. Cancer Res. 66, 10671–10676.
Nishizaki, M., Fujiwara, T., Tanida, T., Hizuta, A., Nishimori, H., Tokino, T.,
Nakamura, Y., Bouvet, M., Roth, J.A., and Tanaka, N. (1999). Recombinant
adenovirus expressing wild-type p53 is antiangiogenic: a proposed mecha-
nism for bystander effect. Clin. Cancer Res. 5, 1015–1023.
Pello, O.M., De Pizzol, M., Mirolo, M., Soucek, L., Zammataro, L., Amabile, A.,
Doni, A., Nebuloni, M., Swigart, L.B., Evan, G.I., et al. (2012). Role of c-MYC in
alternative activation of human macrophages and tumor-associated macro-
phage biology. Blood 119, 411–421.
Ruffell, B., and Coussens, L.M. (2015). Macrophages and therapeutic resis-
tance in cancer. Cancer Cell 27, 462–472.
Sablina, A.A., Budanov, A.V., Ilyinskaya, G.V., Agapova, L.S., Kravchenko,
J.E., and Chumakov, P.M. (2005). The antioxidant function of the p53 tumor
suppressor. Nat. Med. 11, 1306–1313.
Schauer, I.G., Zhang, J., Xing, Z., Guo, X., Mercado-Uribe, I., Sood, A.K.,
Huang, P., and Liu, J. (2013). Interleukin-1b promotes ovarian tumorigenesis
through a p53/NF-kB-mediated inflammatory response in stromal fibroblasts.
Neoplasia 15, 409–420.
Schwitalla, S., Fingerle, A.A., Cammareri, P., Nebelsiek, T., Go¨ktuna, S.I.,
Ziegler, P.K., Canli, O., Heijmans, J., Huels, D.J., Moreaux, G., et al. (2013a).
Intestinal tumorigenesis initiated by dedifferentiation and acquisition of
stem-cell-like properties. Cell 152, 25–38.
Schwitalla, S., Ziegler, P.K., Horst, D., Becker, V., Kerle, I., Begus-Nahrmann,
Y., Lechel, A., Rudolph, K.L., Langer, R., Slotta-Huspenina, J., et al. (2013b).
Loss of p53 in enterocytes generates an inflammatory microenvironment
enabling invasion and lymph node metastasis of carcinogen-induced colo-
rectal tumors. Cancer Cell 23, 93–106.
Shaked, H., Hofseth, L.J., Chumanevich, A., Chumanevich, A.A., Wang, J.,
Wang, Y., Taniguchi, K., Guma, M., Shenouda, S., Clevers, H., et al. (2012).
Chronic epithelial NF-kB activation accelerates APC loss and intestinal tumor
initiation through iNOS up-regulation. Proc. Natl. Acad. Sci. USA 109, 14007–
14012.
Tanaka, T., Kohno, H., Suzuki, R., Hata, K., Sugie, S., Niho, N., Sakano, K.,
Takahashi, M., and Wakabayashi, K. (2006). Dextran sodium sulfate strongly
promotes colorectal carcinogenesis in Apc(Min/+) mice: inflammatory stimuli
by dextran sodium sulfate results in development of multiple colonic neo-
plasms. Int. J. Cancer 118, 25–34.
Terzian, T., Wang, Y., Van Pelt, C.S., Box, N.F., Travis, E.L., and Lozano, G.
(2007). Haploinsufficiency of Mdm2 and Mdm4 in tumorigenesis and develop-
ment. Mol. Cell. Biol. 27, 5479–5485.CeTerzic, J., Grivennikov, S., Karin, E., and Karin, M. (2010). Inflammation and
colon cancer. Gastroenterology 138, 2101–2114.e5.
Vassilev, L.T., Vu, B.T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z.,
Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004). In vivo activation
of the p53 pathway by small-molecule antagonists of MDM2. Science 303,
844–848.
Vousden, K.H., and Prives, C. (2009). Blinded by the Light: The Growing
Complexity of p53. Cell 137, 413–431.
Xiong, S., Van Pelt, C.S., Elizondo-Fraire, A.C., Liu, G., and Lozano, G. (2006).
Synergistic roles of Mdm2 and Mdm4 for p53 inhibition in central nervous sys-
tem development. Proc. Natl. Acad. Sci. USA 103, 3226–3231.
Yamanishi, Y., Boyle, D.L., Pinkoski, M.J., Mahboubi, A., Lin, T., Han, Z., Zvai-
fler, N.J., Green, D.R., and Firestein, G.S. (2002). Regulation of joint destruc-
tion and inflammation by p53 in collagen-induced arthritis. Am. J. Pathol.
160, 123–130.
Zhang, Q., He, X., Chen, L., Zhang, C., Gao, X., Yang, Z., and Liu, G. (2012).
Synergistic regulation of p53 by Mdm2 and Mdm4 is critical in cardiac endo-
cardial cushion morphogenesis during heart development. J. Pathol. 228,
416–428.
Zheng, S.J., Lamhamedi-Cherradi, S.E., Wang, P., Xu, L., and Chen, Y.H.
(2005). Tumor suppressor p53 inhibits autoimmune inflammation and macro-
phage function. Diabetes 54, 1423–1428.ll Reports 13, 888–897, November 3, 2015 ª2015 The Authors 897
